SAN DIEGO, March 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its subsidiary HempMeds® Mexico garnered national news headlines across Mexico for the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of its RSHO-X™ product in treating children with severe epilepsy. HempMeds® Mexico was the first company to receive government import permits for its cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™) via the Mexican Health Department COFEPRIS.
An article from Mexico newspaper Reforma, “Ayuda cannabidiol a 84% de pacientes,” or “Cannabidiol helps 84% of patients,” explained how 84 percent of children with epilepsy treated with RSHO-X™ halved the number of seizures they suffer from, according to this first clinical study on the use of cannabis in patients with Lennox-Gastaut syndrome in Mexico.
“We are proud that our cannabidiol (CBD) hemp oil product, without THC, has enabled 17% of patients in the study to experience 100 percent relief from their seizures, the best results of any product/medication in the world regarding the reduction of seizures in Lennox-Gastaut patients,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is exciting to see such widespread news coverage of these study results by the Mexico media, as studies that prove the therapeutic benefits of CBD like Dr. Garza’s study will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe. In addition, as news spreads of this revolutionary treatment for diseases such as epilepsy, more patients and families that suffer from debilitating medical conditions will receive help with medical marijuana.”
The study included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of 4. Of those 39 patients, who took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced a 50% or greater reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and seven reported a complete elimination of all seizures (17%) over a four-month period, with zero reported side effects.
Results of this study are set to be published in the near future. To view the study, click here.
Other major national Mexico outlets that have reported the results of Dr. Garza’s epilepsy study with RSHO-X™ include:
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact: Andrew Hard
Chief Executive Officer
P: 888-829- 0070